Multiparametric MRI as an early biomarker of individual therapy effects during concomitant treatment of brain tumours

The aim of this study was to determine the ability of multiparametric MRI to identify the early effects of individual treatment, during combined chemo‐radiotherapy on brain tumours. Eighty male rats bearing 9L gliosarcomas were randomized into four groups: untreated, anti‐angiogenic therapy (SORA gr...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:NMR in biomedicine 2015-09, Vol.28 (9), p.1163-1173
Hauptverfasser: Lemasson, Benjamin, Bouchet, Audrey, Maisin, Cécile, Christen, Thomas, Le Duc, Géraldine, Rémy, Chantal, Barbier, Emmanuel L., Serduc, Raphaël
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1173
container_issue 9
container_start_page 1163
container_title NMR in biomedicine
container_volume 28
creator Lemasson, Benjamin
Bouchet, Audrey
Maisin, Cécile
Christen, Thomas
Le Duc, Géraldine
Rémy, Chantal
Barbier, Emmanuel L.
Serduc, Raphaël
description The aim of this study was to determine the ability of multiparametric MRI to identify the early effects of individual treatment, during combined chemo‐radiotherapy on brain tumours. Eighty male rats bearing 9L gliosarcomas were randomized into four groups: untreated, anti‐angiogenic therapy (SORA group), microbeam radiation therapy (MRT group) and both treatments (MRT+SORA group). Multiparametric MRI (tumour volume, diffusion‐weighted MR imaging (ADC), blood volume fraction (BVf), microvessel index (VSI), vessel wall integrity (AUCP846) and tissue oxygen saturation (StO2)) was performed 1 day before and 2, 5 and 8 days after treatment initiation. Unpaired t‐tests and one‐way ANOVA were used for statistical analyses. Each MR parameter measured in our protocol was revealed to be sensitive to tumour changes induced by any of the therapies used (individually or combined). When compared with untreated tumours, SORA induced a decrease in BVf, VSI, StO2 and AUCP846, MRT generated an increase in ADC and AUCP846 and combined therapies yielded mixed effects: an increase in ADC and AUCP846 and a decrease in BVf, StO2 and AUCP846. MRT and MRT+SORA significantly slowed tumour growth. Despite these two groups presenting with similar tumour sizes, the information yielded from MR multiparameter assessment indicated that, when used concomitantly, each therapy induced distinguishable and appreciable physiological changes in the tumour. Our results suggest that multiparametric MRI can monitor the effects of individual treatments, used concomitantly, on brain tumours. Such monitoring would be useful for the detection of tumour resistance to drug/radiotherapy in patients undergoing concomitant therapies. Copyright © 2015 John Wiley & Sons, Ltd. The goal of this study was to evaluate if a multiparametric MRI (diffusion, vessel size, blood volume, oxygenation and permeability) was able to identify early effects of individual treatment during a combined chemo‐radiotherapy on a 9L gliosarcoma. Although radio and chemo‐radio groups presented similar tumour sizes, the information provided by multiparametric MRI allowed us to distinguish the effect of each therapy when used concomitantly. Such monitoring could be useful to detect tumour escape from drug/radiotherapy in patients under concomitant therapies.
doi_str_mv 10.1002/nbm.3357
format Article
fullrecord <record><control><sourceid>proquest_hal_p</sourceid><recordid>TN_cdi_hal_primary_oai_HAL_hal_01236292v1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3778093411</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5247-e888876fd923dc47860b286c6ee1b8743b5645b8b00337bd06f0fa918b58edfe3</originalsourceid><addsrcrecordid>eNqNkdtrFDEUh4ModlsF_wIJ-NI-TJvbJJnH2jvsVvD6GJKZMzZ1LmuSqe5_b9ZdVygI5iUhfOfjnPND6BUlx5QQdjK4_pjzUj1BM0qqqqCiYk_RjFQlK7jQZA_tx3hPCNGCs-doj0nGBNNqhqbF1CW_tMH2kIKv8eL9DbYR2wGDDd0KOz_2NnyDgMcW-6HxD76ZbIfTHQS7XGFoW6hTxM0U_PAV1-NQj71Pdkg4BbCph_zKpS5YP-A09eMU4gv0rLVdhJfb-wB9urz4eHZdzN9d3Zydzou6ZEIVoPNRsm0qxptaKC2JY1rWEoA6rQR3pRSl044QzpVriGxJayuqXamhaYEfoKON9852Zhl8nmRlRuvN9encrP8IZVyyij3QzB5u2GUYv08Qk-l9rKHr7ADjFA1VpKJS5G3-Dyp4SbReW988Qu_zAoY89G-KMFZy_VdYhzHGAO2uWUrMOmGTEzbrhDP6eiucXA_NDvwTaQaKDfDDd7D6p8jcvl1shVvexwQ_d3zO3EjFVWm-3F4Z_eHy_PO5ULn0F2ZMvVY</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1704022538</pqid></control><display><type>article</type><title>Multiparametric MRI as an early biomarker of individual therapy effects during concomitant treatment of brain tumours</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Lemasson, Benjamin ; Bouchet, Audrey ; Maisin, Cécile ; Christen, Thomas ; Le Duc, Géraldine ; Rémy, Chantal ; Barbier, Emmanuel L. ; Serduc, Raphaël</creator><creatorcontrib>Lemasson, Benjamin ; Bouchet, Audrey ; Maisin, Cécile ; Christen, Thomas ; Le Duc, Géraldine ; Rémy, Chantal ; Barbier, Emmanuel L. ; Serduc, Raphaël</creatorcontrib><description>The aim of this study was to determine the ability of multiparametric MRI to identify the early effects of individual treatment, during combined chemo‐radiotherapy on brain tumours. Eighty male rats bearing 9L gliosarcomas were randomized into four groups: untreated, anti‐angiogenic therapy (SORA group), microbeam radiation therapy (MRT group) and both treatments (MRT+SORA group). Multiparametric MRI (tumour volume, diffusion‐weighted MR imaging (ADC), blood volume fraction (BVf), microvessel index (VSI), vessel wall integrity (AUCP846) and tissue oxygen saturation (StO2)) was performed 1 day before and 2, 5 and 8 days after treatment initiation. Unpaired t‐tests and one‐way ANOVA were used for statistical analyses. Each MR parameter measured in our protocol was revealed to be sensitive to tumour changes induced by any of the therapies used (individually or combined). When compared with untreated tumours, SORA induced a decrease in BVf, VSI, StO2 and AUCP846, MRT generated an increase in ADC and AUCP846 and combined therapies yielded mixed effects: an increase in ADC and AUCP846 and a decrease in BVf, StO2 and AUCP846. MRT and MRT+SORA significantly slowed tumour growth. Despite these two groups presenting with similar tumour sizes, the information yielded from MR multiparameter assessment indicated that, when used concomitantly, each therapy induced distinguishable and appreciable physiological changes in the tumour. Our results suggest that multiparametric MRI can monitor the effects of individual treatments, used concomitantly, on brain tumours. Such monitoring would be useful for the detection of tumour resistance to drug/radiotherapy in patients undergoing concomitant therapies. Copyright © 2015 John Wiley &amp; Sons, Ltd. The goal of this study was to evaluate if a multiparametric MRI (diffusion, vessel size, blood volume, oxygenation and permeability) was able to identify early effects of individual treatment during a combined chemo‐radiotherapy on a 9L gliosarcoma. Although radio and chemo‐radio groups presented similar tumour sizes, the information provided by multiparametric MRI allowed us to distinguish the effect of each therapy when used concomitantly. Such monitoring could be useful to detect tumour escape from drug/radiotherapy in patients under concomitant therapies.</description><identifier>ISSN: 0952-3480</identifier><identifier>EISSN: 1099-1492</identifier><identifier>DOI: 10.1002/nbm.3357</identifier><identifier>PMID: 26224287</identifier><language>eng</language><publisher>England: Blackwell Publishing Ltd</publisher><subject>Angiogenesis Inhibitors - therapeutic use ; Animals ; anti-angiogenic ; Bioengineering ; Biomarkers ; blood volume ; Brain Neoplasms - pathology ; Brain Neoplasms - therapy ; Cancer ; glioma ; Imaging ; Life Sciences ; Magnetic Resonance Imaging - methods ; Male ; MRI ; multiparametric ; oxygenation ; permeability ; Precision Medicine ; Rats ; Rats, Inbred F344 ; vessel size</subject><ispartof>NMR in biomedicine, 2015-09, Vol.28 (9), p.1163-1173</ispartof><rights>Copyright © 2015 John Wiley &amp; Sons, Ltd.</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5247-e888876fd923dc47860b286c6ee1b8743b5645b8b00337bd06f0fa918b58edfe3</citedby><cites>FETCH-LOGICAL-c5247-e888876fd923dc47860b286c6ee1b8743b5645b8b00337bd06f0fa918b58edfe3</cites><orcidid>0000-0002-8791-9145 ; 0000-0002-4952-1240 ; 0000-0003-0446-3531</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fnbm.3357$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fnbm.3357$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>230,314,776,780,881,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26224287$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://hal.science/hal-01236292$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Lemasson, Benjamin</creatorcontrib><creatorcontrib>Bouchet, Audrey</creatorcontrib><creatorcontrib>Maisin, Cécile</creatorcontrib><creatorcontrib>Christen, Thomas</creatorcontrib><creatorcontrib>Le Duc, Géraldine</creatorcontrib><creatorcontrib>Rémy, Chantal</creatorcontrib><creatorcontrib>Barbier, Emmanuel L.</creatorcontrib><creatorcontrib>Serduc, Raphaël</creatorcontrib><title>Multiparametric MRI as an early biomarker of individual therapy effects during concomitant treatment of brain tumours</title><title>NMR in biomedicine</title><addtitle>NMR Biomed</addtitle><description>The aim of this study was to determine the ability of multiparametric MRI to identify the early effects of individual treatment, during combined chemo‐radiotherapy on brain tumours. Eighty male rats bearing 9L gliosarcomas were randomized into four groups: untreated, anti‐angiogenic therapy (SORA group), microbeam radiation therapy (MRT group) and both treatments (MRT+SORA group). Multiparametric MRI (tumour volume, diffusion‐weighted MR imaging (ADC), blood volume fraction (BVf), microvessel index (VSI), vessel wall integrity (AUCP846) and tissue oxygen saturation (StO2)) was performed 1 day before and 2, 5 and 8 days after treatment initiation. Unpaired t‐tests and one‐way ANOVA were used for statistical analyses. Each MR parameter measured in our protocol was revealed to be sensitive to tumour changes induced by any of the therapies used (individually or combined). When compared with untreated tumours, SORA induced a decrease in BVf, VSI, StO2 and AUCP846, MRT generated an increase in ADC and AUCP846 and combined therapies yielded mixed effects: an increase in ADC and AUCP846 and a decrease in BVf, StO2 and AUCP846. MRT and MRT+SORA significantly slowed tumour growth. Despite these two groups presenting with similar tumour sizes, the information yielded from MR multiparameter assessment indicated that, when used concomitantly, each therapy induced distinguishable and appreciable physiological changes in the tumour. Our results suggest that multiparametric MRI can monitor the effects of individual treatments, used concomitantly, on brain tumours. Such monitoring would be useful for the detection of tumour resistance to drug/radiotherapy in patients undergoing concomitant therapies. Copyright © 2015 John Wiley &amp; Sons, Ltd. The goal of this study was to evaluate if a multiparametric MRI (diffusion, vessel size, blood volume, oxygenation and permeability) was able to identify early effects of individual treatment during a combined chemo‐radiotherapy on a 9L gliosarcoma. Although radio and chemo‐radio groups presented similar tumour sizes, the information provided by multiparametric MRI allowed us to distinguish the effect of each therapy when used concomitantly. Such monitoring could be useful to detect tumour escape from drug/radiotherapy in patients under concomitant therapies.</description><subject>Angiogenesis Inhibitors - therapeutic use</subject><subject>Animals</subject><subject>anti-angiogenic</subject><subject>Bioengineering</subject><subject>Biomarkers</subject><subject>blood volume</subject><subject>Brain Neoplasms - pathology</subject><subject>Brain Neoplasms - therapy</subject><subject>Cancer</subject><subject>glioma</subject><subject>Imaging</subject><subject>Life Sciences</subject><subject>Magnetic Resonance Imaging - methods</subject><subject>Male</subject><subject>MRI</subject><subject>multiparametric</subject><subject>oxygenation</subject><subject>permeability</subject><subject>Precision Medicine</subject><subject>Rats</subject><subject>Rats, Inbred F344</subject><subject>vessel size</subject><issn>0952-3480</issn><issn>1099-1492</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkdtrFDEUh4ModlsF_wIJ-NI-TJvbJJnH2jvsVvD6GJKZMzZ1LmuSqe5_b9ZdVygI5iUhfOfjnPND6BUlx5QQdjK4_pjzUj1BM0qqqqCiYk_RjFQlK7jQZA_tx3hPCNGCs-doj0nGBNNqhqbF1CW_tMH2kIKv8eL9DbYR2wGDDd0KOz_2NnyDgMcW-6HxD76ZbIfTHQS7XGFoW6hTxM0U_PAV1-NQj71Pdkg4BbCph_zKpS5YP-A09eMU4gv0rLVdhJfb-wB9urz4eHZdzN9d3Zydzou6ZEIVoPNRsm0qxptaKC2JY1rWEoA6rQR3pRSl044QzpVriGxJayuqXamhaYEfoKON9852Zhl8nmRlRuvN9encrP8IZVyyij3QzB5u2GUYv08Qk-l9rKHr7ADjFA1VpKJS5G3-Dyp4SbReW988Qu_zAoY89G-KMFZy_VdYhzHGAO2uWUrMOmGTEzbrhDP6eiucXA_NDvwTaQaKDfDDd7D6p8jcvl1shVvexwQ_d3zO3EjFVWm-3F4Z_eHy_PO5ULn0F2ZMvVY</recordid><startdate>201509</startdate><enddate>201509</enddate><creator>Lemasson, Benjamin</creator><creator>Bouchet, Audrey</creator><creator>Maisin, Cécile</creator><creator>Christen, Thomas</creator><creator>Le Duc, Géraldine</creator><creator>Rémy, Chantal</creator><creator>Barbier, Emmanuel L.</creator><creator>Serduc, Raphaël</creator><general>Blackwell Publishing Ltd</general><general>Wiley Subscription Services, Inc</general><general>Wiley</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>8FD</scope><scope>FR3</scope><scope>P64</scope><scope>7X8</scope><scope>1XC</scope><orcidid>https://orcid.org/0000-0002-8791-9145</orcidid><orcidid>https://orcid.org/0000-0002-4952-1240</orcidid><orcidid>https://orcid.org/0000-0003-0446-3531</orcidid></search><sort><creationdate>201509</creationdate><title>Multiparametric MRI as an early biomarker of individual therapy effects during concomitant treatment of brain tumours</title><author>Lemasson, Benjamin ; Bouchet, Audrey ; Maisin, Cécile ; Christen, Thomas ; Le Duc, Géraldine ; Rémy, Chantal ; Barbier, Emmanuel L. ; Serduc, Raphaël</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5247-e888876fd923dc47860b286c6ee1b8743b5645b8b00337bd06f0fa918b58edfe3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Angiogenesis Inhibitors - therapeutic use</topic><topic>Animals</topic><topic>anti-angiogenic</topic><topic>Bioengineering</topic><topic>Biomarkers</topic><topic>blood volume</topic><topic>Brain Neoplasms - pathology</topic><topic>Brain Neoplasms - therapy</topic><topic>Cancer</topic><topic>glioma</topic><topic>Imaging</topic><topic>Life Sciences</topic><topic>Magnetic Resonance Imaging - methods</topic><topic>Male</topic><topic>MRI</topic><topic>multiparametric</topic><topic>oxygenation</topic><topic>permeability</topic><topic>Precision Medicine</topic><topic>Rats</topic><topic>Rats, Inbred F344</topic><topic>vessel size</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lemasson, Benjamin</creatorcontrib><creatorcontrib>Bouchet, Audrey</creatorcontrib><creatorcontrib>Maisin, Cécile</creatorcontrib><creatorcontrib>Christen, Thomas</creatorcontrib><creatorcontrib>Le Duc, Géraldine</creatorcontrib><creatorcontrib>Rémy, Chantal</creatorcontrib><creatorcontrib>Barbier, Emmanuel L.</creatorcontrib><creatorcontrib>Serduc, Raphaël</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><jtitle>NMR in biomedicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lemasson, Benjamin</au><au>Bouchet, Audrey</au><au>Maisin, Cécile</au><au>Christen, Thomas</au><au>Le Duc, Géraldine</au><au>Rémy, Chantal</au><au>Barbier, Emmanuel L.</au><au>Serduc, Raphaël</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Multiparametric MRI as an early biomarker of individual therapy effects during concomitant treatment of brain tumours</atitle><jtitle>NMR in biomedicine</jtitle><addtitle>NMR Biomed</addtitle><date>2015-09</date><risdate>2015</risdate><volume>28</volume><issue>9</issue><spage>1163</spage><epage>1173</epage><pages>1163-1173</pages><issn>0952-3480</issn><eissn>1099-1492</eissn><abstract>The aim of this study was to determine the ability of multiparametric MRI to identify the early effects of individual treatment, during combined chemo‐radiotherapy on brain tumours. Eighty male rats bearing 9L gliosarcomas were randomized into four groups: untreated, anti‐angiogenic therapy (SORA group), microbeam radiation therapy (MRT group) and both treatments (MRT+SORA group). Multiparametric MRI (tumour volume, diffusion‐weighted MR imaging (ADC), blood volume fraction (BVf), microvessel index (VSI), vessel wall integrity (AUCP846) and tissue oxygen saturation (StO2)) was performed 1 day before and 2, 5 and 8 days after treatment initiation. Unpaired t‐tests and one‐way ANOVA were used for statistical analyses. Each MR parameter measured in our protocol was revealed to be sensitive to tumour changes induced by any of the therapies used (individually or combined). When compared with untreated tumours, SORA induced a decrease in BVf, VSI, StO2 and AUCP846, MRT generated an increase in ADC and AUCP846 and combined therapies yielded mixed effects: an increase in ADC and AUCP846 and a decrease in BVf, StO2 and AUCP846. MRT and MRT+SORA significantly slowed tumour growth. Despite these two groups presenting with similar tumour sizes, the information yielded from MR multiparameter assessment indicated that, when used concomitantly, each therapy induced distinguishable and appreciable physiological changes in the tumour. Our results suggest that multiparametric MRI can monitor the effects of individual treatments, used concomitantly, on brain tumours. Such monitoring would be useful for the detection of tumour resistance to drug/radiotherapy in patients undergoing concomitant therapies. Copyright © 2015 John Wiley &amp; Sons, Ltd. The goal of this study was to evaluate if a multiparametric MRI (diffusion, vessel size, blood volume, oxygenation and permeability) was able to identify early effects of individual treatment during a combined chemo‐radiotherapy on a 9L gliosarcoma. Although radio and chemo‐radio groups presented similar tumour sizes, the information provided by multiparametric MRI allowed us to distinguish the effect of each therapy when used concomitantly. Such monitoring could be useful to detect tumour escape from drug/radiotherapy in patients under concomitant therapies.</abstract><cop>England</cop><pub>Blackwell Publishing Ltd</pub><pmid>26224287</pmid><doi>10.1002/nbm.3357</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0002-8791-9145</orcidid><orcidid>https://orcid.org/0000-0002-4952-1240</orcidid><orcidid>https://orcid.org/0000-0003-0446-3531</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 0952-3480
ispartof NMR in biomedicine, 2015-09, Vol.28 (9), p.1163-1173
issn 0952-3480
1099-1492
language eng
recordid cdi_hal_primary_oai_HAL_hal_01236292v1
source MEDLINE; Wiley Online Library Journals Frontfile Complete
subjects Angiogenesis Inhibitors - therapeutic use
Animals
anti-angiogenic
Bioengineering
Biomarkers
blood volume
Brain Neoplasms - pathology
Brain Neoplasms - therapy
Cancer
glioma
Imaging
Life Sciences
Magnetic Resonance Imaging - methods
Male
MRI
multiparametric
oxygenation
permeability
Precision Medicine
Rats
Rats, Inbred F344
vessel size
title Multiparametric MRI as an early biomarker of individual therapy effects during concomitant treatment of brain tumours
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-29T20%3A33%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_hal_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Multiparametric%20MRI%20as%20an%20early%20biomarker%20of%20individual%20therapy%20effects%20during%20concomitant%20treatment%20of%20brain%20tumours&rft.jtitle=NMR%20in%20biomedicine&rft.au=Lemasson,%20Benjamin&rft.date=2015-09&rft.volume=28&rft.issue=9&rft.spage=1163&rft.epage=1173&rft.pages=1163-1173&rft.issn=0952-3480&rft.eissn=1099-1492&rft_id=info:doi/10.1002/nbm.3357&rft_dat=%3Cproquest_hal_p%3E3778093411%3C/proquest_hal_p%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1704022538&rft_id=info:pmid/26224287&rfr_iscdi=true